Rakovina Therapeutics Inc · TSXV:RKV
Rakovina Therapeutics — Investor Presentation (September 2024)
22 slides from Rakovina Therapeutics's investor presentation, September 2024
Slide 1: Transforming Lives for Those Battling Cancer with the Speed & Precision of AI
TSX.V: RKV TRANSFORMING LIVES FOR THOSE BATTLING CANCER WITH THE SPEED & PRECISION OF AI Investor Presentation | Q3 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the investors who will pa
Slide 3: Using AI to Battle Cancer
USING AI TO BATTLE CANCER Our mission has always been about improving the lives of those battling cancer. Now, with a robust Artificial Intelligence (AI) platform on our side, we are moving into a new era of research speed and accuracy. Using our Deep DockingTM platform powered by advanced AI algori
Slide 4: Company Snapshot
COMPANY SNAPSHOT Founded in 2021 to focus Exclusive access to Deep Leveraging robust lead- Experienced leadership on the development of new DockingTM AI Platform to optimization infrastructure with a track-record of DNA-damage (DDR) rapidly screen billions of already established in success response-
Slide 5: Traditional Drug Development Techniques Are Costing Lives
TRADITIONAL DRUG DEVELOPMENT TECHNIQUES ARE COSTING LIVES Patients can not wait long timelines over years to get the treatment they need today and tomorrow. LONG TIMELINES OUTCOMES AND TIMELINES OF TRADITIONAL DRUG DEVELOPMENT 14 YEARS TARGET COMPOUND LEAD OPTIMIZATION PRE-CLINICAL PHASE 1 PHASE II
Slide 6: Traditional Drug Development Limits Drug Discovery
TRADITIONAL DRUG DEVELOPMENT LIMITS DRUG DISCOVERY Significant obstacles challenge the advancement of life-changing innovations in new drug therapeutics. HIGH COSTS HIGH RISKS The high costs required to establish and maintain screening Drug candidate failure rate can be very high and costly due to p
Slide 7: A New Era with Deep Docking AI Collaboration
A NEW ERA WITH DEEP DOCKING AI COLLABORATION • Exclusive access to Deep Docking AI platform for DNA-damage response targets • Rakovina Therapeutics owns rights to all novel drug candidates generated through the collaboration • Program overseen by Rakovina scientific advisory board member, Dr. Artem
Slide 8: The Deep Docking AI Platform Revolutionizes Drug Development
THE DEEP DOCKING AI PLATFORM REVOLUTIONIZES DRUG DEVELOPMENT HIGH YIELD DRUG SHORTENED TIMELINES MAXIMIZING SUCCESS DISCOVERY & REDUCED COST Deep learning (DL) method has AI algorithms screen billions of drug Deep Docking is optimized to search superior performance compared to candidates in months v
Slide 9: Concurrent Research: Variational AI Enki Platform
CONCURRENT RESEARCH: VARIATIONAL AI ENKI PLATFORM TARGETING DDR KINASE ACCELERATING PROGRESS WITH MAXIMIZING SUCCESS AND INHIBITORS MULTIPLE AI PROGRAMS PIPELINE EXPANSION Rakovina Therapeutics is expanding its The Enki Generative AI can identify DDR Generative AI enhances success rates AI-driven dr
Slide 10: Deep Docking AI Platform: A Real-World Paradigm Shift
DEEP DOCKING AI PLATFORM: A REAL-WORLD PARADIGM SHIFT Deep Docking AI Real-World Impact on COVID 19 1.4B “The team behind Deep Docking partnered with Nvidia, Dell and UBC Advanced Research Computing (ARC) to identify Drug Candidates potential COVID-19 therapeutics from large libraries. Even Screened
Slide 11: DNA-Damage Response (DDR)
DNA-DAMAGE RESPONSE (DDR) 75% of solid tumors harbor a DDR defect1 $18B DDR annual market potential by 20302 • DDRs are naturally occurring mechanisms that detect and repair DNA damage within our cells • Many cancers harbor a defect in these natural repair mechanisms allowing mutations to accumulate
Slide 12: Combining Deep Docking AI Platform with Rakovina Capabilities
COMBINING THE DEEP DOCKING AI PLATFORM WITH RAKOVINA CAPABILITIES FOR RAPID DDR DRUG DEVELOPMENT COMPOUND SCREENING & LEAD OPTIMIZATION PHASE only 3-4 months from 3 years COMPOUND SCREENING DRUG VALIDATION LAB QUALIFIED CLINICAL LEADS 5B+ ULTRA LARGE DATASETS INTEGRATED PLATFORM FOR ADVANCING DDR DR
Slide 13: Rakovina Therapeutics' Drug Development Portfolio
RAKOVINA THERAPEUTICS’ DRUG DEVELOPMENT PORTFOLIO Development Stage Multiple high-value DDRi Drug targets already Indication Development Pipeline Drug Lead Pre- Clinical validated. Discovery Optimization clinical Trials ✓ PARP kt-3283 PARP-resistant ✓ ATM adult & childhood kt-3000 series cancers ✓ C
Slide 14: First AI Target: A CNS Penetrant Selective Inhibitor of PARP-1
FIRST AI TARGET: A CNS PENETRANT SELECTIVE INHIBITOR OF PARP-1 • PARP is a type of enzyme that helps repair DNA damage in cells • PARP inhibitors are a type of cancer drug that work by preventing cancer cells from repairing, allowing them to die • 1st generation PARP-1/2 inhibitors have achieved com
Slide 15: Investments in DNA-Damage Response by Multi-National Pharmaceutical Corporations
INVESTMENTS IN DNA-DAMAGE RESPONSE BY MULTI-NATIONAL PHARMACEUTICAL CORPORATIONS RECENT DDR TRANSACTIONS Oct 2023 PARP-inhibitor $1.5B ($161M upfront) FDA status at signing: preclinical License Agreement Jun 2022 $1.2B ($125M upfront) ATR-inhibitor >$25B FDA status at signing: preclinical License Ag
Slide 16: H2 2024 / H1 2025 Deep Docking AI Milestones
H2 2024 / H1 2025 DEEP DOCKINGTM AI MILESTONES kt-2000AI Best-in-class PARP-1 selective, brain penetrant cancer therapy TIMELINE Months (from April 2024) Early fall 2024 Establish Collaboration & Initiate Training of AI ➔ Receipt of initial AI Output Deep Docking of >7 billion molecules into PARP-1
Slide 17: Experienced Team with a Track Record of Success
EXPERIENCED TEAM WITH A TRACK RECORD OF SUCCESS Our team has deep experience in drug discovery research, preclinical ARTEM CHERKASOV, PHD and clinical development and regulatory affairs necessary to advance SAB/Senior AI & Medicinal Chemistry Advisor breakthrough innovations to become potential life
Slide 18: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD DENNIS BROWN, PHD ARTEM CHERKASOV, PHD Chair, Scientific Advisory Board (SAB)/Director SAB/Senior AI & Medicinal Chemistry Advisor • Involved in cancer drug discovery and development for 35+ years and currently serves as a • Professor at UBC's Department of Urologic Science
Slide 19: Market Summary
MARKET SUMMARY OWNERSHIP SUMMARY EXCHANGE TSX Venture Exchange (TSXV) Edison Oncology SYMBOL RKV Holding Corp. 26.9% SECTOR / INDUSTRY Biopharmaceuticals / Oncology Institution 26 WEEK RANGE1 CAD $0.07 -0.14 / Retail 62.7% SHARES OUTSTANDING 90,289,175 FULLY DILUTED 128,184,676 Reporting WARRANTS2 2
Slide 20: Why Invest in Rakovina Therapeutics
WHY INVEST IN RAKOVINA THERAPEUTICS A paradigm shift in drug discovery and therapeutic intervention to treat cancer. $18B SUPERIOR DEEP REAL-WORLD UNMATCHED BRING-TO-MARKET ADDRESSABLE DOCKINGTM AI PROVEN INTEGRATED DRUG MANAGEMENT MARKET PLATFORM TECHNOLOGY VALIDATION TEAM Broad cancer application
Slide 21: In the Media
IN THE MEDIA READ ARTICLE Source: https://www.theglobeandmail.com/investing/markets/stocks/RKV-X/pressreleases/24167118/rakovina-therapeutics-top-10-undervalued-biotechnology-industry-stocks-rkv/ TSX.V: RKV / 21
Slide 22: Over 70% of Pharmaceutical Breakthroughs Stem from Small Biotech Companies
OVER 70% OF PHARMACEUTICAL BREAKTHROUGHS STEM FROM THE EFFORTS OF SMALL BIOTECH COMPANIES info@rakovinatherapeutics.com LIKE RAKOVINA rakovinatherapeutics.com THERAPEUTICS 105 – 1008 Beach Avenue Vancouver, British Columbia Canada V6E 1T7 TSX.V: RKV / 22
Rakovina Therapeutics — Investor Presentation (September 2024) on 6ix